BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 200.9% in May

BiomX Inc. (NYSEAMERICAN:PHGE) saw a significant increase in short interest in May. As of May 29th, there was short interest totaling 594,279 shares, an increase of 200.9% from the May 14th total of 197,532 shares. Approximately 7.5% of the company’s stock are sold short. Based on an average trading volume of 38,808,369 shares, the short-interest ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright lowered shares of BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, BiomX currently has a consensus rating of “Hold” and a consensus price target of $26.00.

Insider Activity

In related news, Director Reuven Yeganeh sold 530,000 shares of BiomX stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total transaction of $2,650,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 21.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC acquired a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to its most recent filing with the SEC. The fund acquired 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by institutional investors.

BiomX Trading Up 10.6%

BiomX stock opened at $0.71 on Friday. BiomX has a 12 month low of $0.36 and a 12 month high of $14.71. The business’s 50 day simple moving average is $1.37 and its 200 day simple moving average is $3.19. The company has a market cap of $7.90 million, a price-to-earnings ratio of -0.22 and a beta of 1.18.

BiomX (NYSEAMERICAN:PHGE) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $7.38 earnings per share (EPS) for the quarter. As a group, equities research analysts forecast that BiomX will post -5.85 earnings per share for the current fiscal year.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.